ReviewTherapeutics and clinical risk management2017
Dupilumab in the management of moderate-to-severe asthma: the data so far.
Review in Therapeutics and clinical risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.Respiratory research · 2019Pooled it
- Dupilumab-associated anti-glomerular basement membrane nephritis in a patient with eosinophilic granulomatosis with polyangiitis: a case report.BMC nephrology · 2025Article
- Design of Glycoengineered IL-4 Antagonists Employing Chemical and Biosynthetic Glycosylation.ACS omega · 2023Article
- CD30 Regulation of IL-13-STAT6 Pathway in Breast Implant-Associated Anaplastic Large Cell Lymphoma.Aesthetic surgery journal · 2023Article
- Article
- Review
- Case Report: Drug-Induced (Neuro) Sarcoidosis-Like Lesion Under IL4 Receptor Blockade With Dupilumab.Frontiers in neurology · 2022Article
- COVID-19, Eosinophils, and Biologicals for Severe Asthma.Frontiers in allergy · 2022Article
- The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.Current research in immunology · 2022Review
- Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps.International journal of molecular sciences · 2021Review
- Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.Multidisciplinary respiratory medicine · 2021Article
- Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality.Frontiers in genetics · 2021Article
- Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: A retrospective analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Article
- Monoclonal Antibodies and Airway Diseases.International journal of molecular sciences · 2020Review
- Article
- Combined administration of anti-IL-13 and anti-IL-17A at individually sub-therapeutic doses limits asthma-like symptoms in a mouse model of Th2/Th17 high asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Article
- Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems.Journal of asthma and allergy · 2019Review
- A case of chronic eosinophilic pneumonia in a patient treated with dupilumab.Therapeutics and clinical risk management · 2019Article
- AnticalinBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma constitutes illness in a relatively small proportion of all patients with asthma, but it is a major public health problem - with considerable effect on morbidity, mortality, as well as a high burden on health care resources. Regardless of effective treatments being widely available and the existence of treatment guidelines, a large population of severe asthma cases remain uncontrolled. Achieving and maintaining asthma control in this group of patients is, therefore, of utmost importance. The recognition of distinct inflammatory phenotypes within this population has driven the development of targeted biological therapies - particularly, selective targeted monoclonal antibodies (mAbs). It is noteworthy that in approximately 50% of these patients, there is strong evidence of the pathogenic role of T helper type-2 (Th2) cytokines, such as interleukin (IL)-4 and IL-13, orchestrating the eosinophilic and allergic inflammatory processes. Among the recently developed antiasthma biologic drugs, the mAb dupilumab is very promising given its ability to inhibit the biological effects of both IL-4 and IL-13. In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.